Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study

As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily pre-treated ovarian carcinoma patients. We retrospectively reviewed 43 patients with re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bulletin du cancer 2011-10, Vol.98 (9), p.E80-E89
Hauptverfasser: Asmane, Irène, Kurtz, Jean-Emmanuel, Bajard, Agathe, Guastalla, Jean-Paul, Meeus, Pierre, Tredan, Olivier, Labidi Galy, Intidhar, Moullet, Isabelle, Ardisson, Philippe, Vincent, Lionel, Coeffic, David, Dufresne, Armelle, Bergerat, Jean-Pierre, Ray-Coquard, Isabelle
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!